Prostate specific antigen rapid test kits
was detected quantitatively by double antibody sandwich enzyme linked immunosorbent assay (ELISA). Prostate specific antigen rapid test kits is only for scientific research, not for clinical diagnosis.
Prostate specific antigen (PSA), also known as gamma-seminal plasma or Kallikrein 3 (KLK3), is a glycoprotein encoded by the KLK3 gene in humans. PSA is a member of the kallikrein-related peptidase family, which is secreted by prostate epithelial cells. Ejaculation produces PSA, which liquefies semen clots and allows sperm to swim freely. PSA also dissolves cervical mucus, allowing sperm to enter the uterus. Men with normal prostate have only a small amount of PSA in their serum, while patients with prostate cancer or other prostatic dysfunction tend to have higher levels of PSA in their serum. Obesity has been reported to reduce serum PSA levels. Prostatitis, irritation and benign prostatic hyperplasia increase PSA content and produce false positive results. PSA is not the only marker for prostate cancer, but also for prostatitis or benign prostatic hyperplasia. Thirty percent of patients with high levels of PSA were diagnosed with prostate cancer after biopsy. Clinical practice guidelines for prostate cancer screening vary and are controversial, as uncertainty about whether the benefits of screening are greater than the risks of overdiagnosis and overtreatment.